and outer coatings were aimed, respectively, at delaying the onset of release through swelling/erosion processes, extending the duration of the lag phase by slowing down water penetration into the underlying functional layer, and overcoming variable gastric residence time. In vitro studies showed that neither insulin nor sodium glycocholate were released from the three-layer system during 2 h of testing in 0.1 N HCl, while complete release of the protein and of the enhancer 25 occurred in phosphate buffer, pH 6.8, after consistent lag phases. No significant changes were noticed in the release profiles following twelve-month storage at 4 °C. Oral administration of the novel formulation to diabetic rats elicited a peak in the plasma insulin concentrations after 6 h, which was associated with a sharp decrease in the glycemic levels. The relative bioavailability and pharmacological availability of such a formulation, as determined vs the uncoated tablets, were 2.2 30 and 10.3, respectively. Based on these results, the three-layer system presented was considered a potentially interesting tool for oral colonic delivery of insulin and adjuvant compounds.
Introduction
Colon delivery is under extensive investigation as a promising approach to improve the oral bioavailability of peptide and protein drugs [1] [2] [3] . Although the large bowel fails to be ideally suited 40 for absorption, it may indeed offer a number of advantages over the small intestine, including prolonged transit time, low levels of peptidases and good responsiveness to permeation enhancers [4] [5] [6] . A swellable/erodible time-dependent colon delivery platform (Chronotopic™) based on lowviscosity hydroxypropyl methylcellulose (HPMC) coating was demonstrated to provide the pursued in vitro and in vivo release of low molecular weight drugs [7, 8] . Accordingly, this system was90
Coating of minitablet cores
Minitablets were first coated by a rotary fluid bed (GPCG 1.1, Glatt, Binzen, Germany) with an aqueous solution of Methocel ® E50 (8.0% w/V) and PEG 400 (0.8% w/V). The resulting HPMCcoated insulin minitablets (one-layer) were then coated by a bottom-spray fluid bed with diluted
(1:1) Eudragit ® NE 30 D containing 20% w/w (on dry polymer) of Explotab ® V17 as previously 95 described [14, 15] . The two-layer formulation was finally enteric coated with a hydro-alcoholic solution of Aqoat ® AS (6% w/w in 3:1 w/w ethanol:water) by a ventilated coating pan (GS, Osteria
Grande, Italy) under the following operating conditions: 150 g batch size; 60 °C inlet air temperature; 32-34 °C product temperature; 0.75 and 0.50 bar nebulizing and pattern pressure, respectively; 8 g/min spray rate; 30 rpm rotating speed; 11-12 cm nozzle -product distance. The 100 three-layer formulation was finally cured at 40°C in an oven for 30 min. The Methocel ® E50 /PEG 400, Eudragit ® NE/Explotab ® V17 and Aqoat ® AS coating levels were determined by subtracting the weight of units obtained at each coating step from that of the starting units (n=20), i.e.
minitablets, one-layer systems or two-layer systems, and expressed as mg of solid applied per cm 2 .
The surface and cross-section of the coated units were analyzed by scanning electron microscopy 105 (SEM, Sigma, Zeiss, Oberkochen, Germany; gold sputtering 10 nm).
In vitro release studies
In vitro release studies (n=6) were carried out by means of an adapted three-position disintegration testing apparatus. This was selected in order to overcome adhesion of the hydrated HPMC coating 110 to the vessels of a paddle dissolution apparatus [17] . Each unit, either a minitablet or a coated system, was inserted into a basket-rack assembly so that only one of the 6 available tubes was filled.
During the test, every basket-rack assembly moved at a rate of 31 cycles/min in a separate vessel containing 160 mL of appropriate medium. A reduced volume of fluid was used so that insulin and sodium glycocholate released from each single uncoated or coated minitablet could be assayed.
Sink conditions were maintained throughout the whole test. Non-gastroresistant units were tested in phosphate buffer, pH 6.8, while enteric-coated ones were tested in 0.1 N HCl for 2 h and then in the phosphate buffer. The medium temperature of was set at 37±1 °C. Fluid samples of 0.5 mL were withdrawn at scheduled time points, and bovine insulin and sodium glycocholate were assayed by RP-HPLC as previously described [10] . Quantitation of insulin and sodium glycocholate was 120 carried out using four-point calibration curves (R 2 >0.99). Asn 21 desamido insulin (A21) was not detected throughout the test. The release study (n=3) of final three-layer systems stored in closed glass vials at 4 °C was repeated after 3 and 12 months.
In vitro lag time was expressed as the time required for 10% drug release in phosphate buffer, pH 6.8 (t 10% ). t 10% was calculated by linear interpolation of the experimental data immediately before 125 and after this release percentage. Louis, Missouri, US) using a calibration curve obtained from standard glucose solutions. Insulin was assayed in plasma by ELISA using a human insulin-specific ELISA kit (Sigma-Aldrich, St.
In vivo studies
Louis, Missouri, US). Plasma samples of 10 µL were diluted to 100 µL with phosphate buffered 140 saline before analysis.
Glucose and insulin concentration data were processed by using Kinetica Software (ThermoScientific, Rodano, Italy). Pharmacological availability was calculated as the area above the glucose concentration vs time curve considering the initial glucose level as the baseline point (AAC 0→50 h ). The protein bioavailability was calculated as the area under the insulin concentration 145 vs time curve (AUC 0→50 h ). The relative pharmacological availability (PA rel ) and relative bioavailability (BA rel ) of the three-layer system (S) vs the minitablet (M) were also calculated as follows [18] :
In vivo lag time (t lag ) was calculated from the insulin concentration vs time curve as the time to 5%
of AUC 0→50 h .
Statistical analysis
Statistical analysis of in vitro and in vivo data was performed by two-group two-tail unpaired t-155 Student test accounting for heteroscedasticity. The differences were considered significant with p <0.05.
Results and Discussion
The three-layer system depicted in Figure 1 was designed to yield release of insulin into the colon 160 according to a time-dependent approach [1] . Such an approach relies on the relative consistency of small intestinal transit time (SITT) of dosage forms, which was shown to poorly be affected by the characteristics of the administered units and by the fasted/fed state of the subjects [19, 20] . Hence, time-dependent colon delivery systems are generally devised so as to maintain integrity during unpredictable gastric residence and then start a lag phase intended to cover the entire SITT before 165 releasing their drug load. by the underlying erodible layer. The outer film was meant to overcome unpredictable gastric residence that would hinder timely release of insulin into the colon.
Sodium glycocholate was incorporated into the core as an absorption enhancer. According to previous studies, this "active" excipient was selected because of its compatibility with the protein in the solid state and was demonstrated to effectively promote insulin permeation through the 175 intestinal epithelium [10, 21] . Sodium glycocholate was also found to inhibit proteases, which would be beneficial to insulin stability [22] [23] [24] [25] . The gastrointestinal tolerability was another important feature in the permeation enhancer selection, as it is a requisite for the development of safe oral pharmaceutical products [21, 26] . In the case of insulin delivery, this would especially be critical in view of the chronic use of this drug. 180
All spray-coating steps were accomplished without major technical problems. Coated units obtained at each step met pre-set requirements for weight variability (RSD <6%). The HPMC, Eudragit ® NE/Explotab ® V17 and HPMCAS coatings resulted in 30.6, 1.9 and 7.8 mg/cm 2 of each polymer applied, respectively, which corresponded to nominal layer thicknesses of 250, 20 and 100 µm.
SEM analysis performed on the cross-sectioned three-layer systems showed continuous overlapping 185 layers also at the tablet edges (Figure 2) .
In vitro studies were performed to evaluate the effect of the HPMC and Eudragit ® NE/Explotab ® V17 coats on the release of insulin and sodium glycocholate.
The profiles reported in Figures 3a and 4a show that the protein and the adjuvant were rapidly released from the minitablet cores. The HPMC layer markedly delayed the onset of insulin and 190 sodium glycocholate release, as pointed out by Figures 3b and 4b . The Eudragit ® NE/Explotab ® V17 coating enhanced the delaying effect of the HPMC layer, resulting in almost two-fold duration of the lag phase in the case of the protein (Figures 3c and 4c) . The release of sodium glycocholate started generally earlier than that of insulin. This behavior could be ascribed to the greater solubility of sodium glycocholate, at least of 2 orders of magnitude, and its lower molecular weight, which 195 may favor the relevant diffusion through the coatings during swelling. However, either a concurrent or slightly earlier release of the adjuvant might be suitable in vivo for enhancing permeation of the protein through the enteric mucosa [27] [28] [29] . The release rate of both compounds, and particularly of insulin, was decreased in the presence of the Eudragit ® NE/Explotab ® V17 film.
The lag time values (t 10% ) of insulin and sodium glycocholate from each formulation, collected in 200 Table I , were fairly reproducible. Table I ).
The release profiles obtained after 3 and 12 months of storage of the three-layer system at 4 °C 210 showed minor, non-significant differences in terms of release onset as compared with the formulations tested at t=0 ( Figure 6 , Table I ). However, a decreased release rate was observed after 12 months. In this respect, a more extensive investigation into the curing conditions could help understand and overcome possible ageing phenomena.
Overall, the in vitro performance, and in particular the duration of the lag phase observed under 215 simulated intestinal pH conditions, was deemed potentially suitable for colonic release according to in vivo results previously collected from analogous delivery systems [16] .
In vivo studies were comparatively performed by oral administration of the three-layer system, uncoated minitablet and insulin in solution to diabetic rats. Figures 7 and 8 report the insulin and glucose concentration profiles in the blood over time. 220
When dosed as a solution, insulin did not elicit any decrease in glycemia and, in the bloodstream, only fluctuations in a relatively narrow range around its initial concentration were observed. The uncoated minitablets yielded a slight increase in the insulin blood levels. A negligible decrease in the glucose concentration was seen within 3 h from administration but the hyperglycemic levels were rapidly restored. In contrast, the three-layer system brought about a sharp rise in the insulin 225 concentration and decrease in the glucose levels. Statistical analysis of insulin concentration vs.
time profiles pointed out significant differences in the AUC 0→50 h obtained from the three-layer formulation against both the uncoated minitablet and the solution. The bioavailability of insulin from the three-layer system, the uncoated minitablet and the solution was 98.1, 44.5 and 17.7 µg * mL -1 * h, respectively. Analogously, the AAC 0→50 h from the glucose concentration vs. time 230 profiles of the three-layer system was significantly greater as compared with the uncoated minitablet and the solution. The relative insulin bioavailability (BA rel ) of the three-layer system, obtained as the AUC 0→50 h ratio vs the uncoated minitablet, was 2.2, while the relative pharmacological availability (PA rel ), calculated as the AAC 0→50 h ratio between the two formulations, was 10.3. 235
The maximal protein concentration (C max 3.9 ng/mL) and glycemia reduction (about 70%) were obtained after 6 h from administration. Between 5 h and 50 h post-dose, the concentrations of insulin provided by the three-layer system were markedly higher than those detected with the uncoated minitablet and the solution. Lag time, expressed as the time to 5% of AUC 0→50h , was of approximately 5 h. As expected based on previous data, the system was proved to delay the 240 appearance of insulin in the bloodstream for a considerably more extended period of time with respect to the in vitro lag phase [15, 16] . Besides, the rate of protein release into the gastrointestinal tract was such as to yield a prompt pharmacodynamic response at the end of lag time.
Overall, the above-discussed results indicate that, when administering the proposed three-layer system, insulin would rapidly and effectively be absorbed after a lag phase. This delay may have 245 allowed distal intestinal release and permeation of the protein. From literature data on gastrointestinal transit in rats, it could be inferred that insulin might have been absorbed while the delivery system was located in the ileo-colonic region [30] [31] [32] 64.4 ± 6.9 52.0 ± 6.3 Three-layer system (3 months) 73.7 ± 3.8 60.1 ± 2.5 Three-layer system (12 months) 70.6 ± 7.0 57.3 ± 2.8
